Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Septerna, Inc.NASDAQ: SEPN
Net Change in Cash · Q3 FY2026 · quarter ended Sep 2026
Net change in cash declines year over year
Q3 FY2026 net change in cash of $82.46M fell 36.9% year over year, ahead of the -166.0% change in trailing-twelve-month net change in cash. Sequentially, it rose 531.6% from the prior quarter.
Context
- Net change in cash amounted to 255.7% of revenue in FY2025, down 13671.1 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -36.9% holds above the trailing-twelve-month pace of -166.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (117.47M) USD
- Year-over-year change
- -178.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (117.47M) | -178.5% |
| FY2024 | 2024-12-31 | 149.71M | +158.5% |
| FY2023 | 2023-12-31 | 57.92M | +961.0% |
| FY2022 | 2022-12-31 | 5.46M | — |
Net Change in Cash vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's LTM Sep 2026 net change in cash of $152.87M is the 2nd largest of the 7 companies compared; the peer median is $37.69M.
- Its year-over-year change of -166.0% is the 5th highest of 6, against a peer median of +52.5%.
- Net change in cash amounts to 158.8% of revenue for SEPN, versus a peer median of 330.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $357.83M | +52.5% | — | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $152.87M | -166.0% | — | 158.8% |
| LTM Mar 2026 | $95.61M | -136.2% | -57.8% | 478.0% | |
| LTM Mar 2026 | $67.03M | +416.2% | — | 181.9% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $61.23M | -167.8% | +31.0% | — |
KLRAKailera Therapeutics, Inc. | FY2025 | $14.15M | — | — | — |
| LTM Mar 2026 | $9.2M | +108.4% | -58.2% | — | |
| Peer median (excluding SEPN) | $37.69M | +52.5% | -57.8% | 330.0% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (27.68M) | 4.18M | (71.8M) | (48.88M) |
| Depreciation & Amortization | 577K | 848K | 1.4M | 1.6M |
| Deferred Income Tax | 0 | 491K | (491K) | 0 |
| Stock-Based Compensation | 1.52M | 1.62M | 3.15M | 8.48M |
| Change in Working Capital | 1.75M | 926K | 248K | 162.78M |
| Accounts Receivables | 0 | (151K) | (20K) | (10.19M) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.73M | (653K) | 723K | 6.6M |
| Other Working Capital | 20K | 1.73M | (455K) | 166.36M |
| Other Non-Cash Items | 530K | (46.79M) | 18K | (13.79M) |
| Operating Cash Flow | (23.3M) | (38.72M) | (67.47M) | 110.19M |
| Capital Expenditures | (1.29M) | (2.88M) | (2.1M) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.5M |
| Purchases of Investments | 0 | 0 | (213.39M) | (450.95M) |
| Sales of Investments | 0 | 0 | 32.27M | 209.62M |
| Other Investing Activities | 0 | 25M | 22.63M | 0 |
| Investing Cash Flow | (1.29M) | 22.12M | (160.6M) | (229.35M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 82K | 0 | 302.79M | 1.69M |
| Common Stock Repurchased | 0 | (1K) | (1K) | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 52K | 0 |
| Financing Cash Flow | 30.05M | 74.52M | 377.78M | 1.69M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.46M | 57.92M | 149.71M | (117.47M) |
| Free Cash Flow | (24.59M) | (41.6M) | (69.57M) | 109.67M |
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.